MetaVia Inc., a clinical-stage biotech company focused on cardiometabolic diseases, recently presented updates on its pipeline of next-generation therapeutics targeting obesity and MASH. The company's investigational drug, DA-1726, a novel GLP1R/GCGR dual agonist, is currently in Phase 1 trials and has shown promising results with significant weight loss and reductions in fasted glucose levels. Additionally, DA-1241, targeting MASH, has met its Phase 2a primary endpoint, demonstrating direct hepatic effects and a strong safety profile. MetaVia continues to explore further studies and regulatory interactions for these treatments. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.